摘要
目的研究重组葡激酶（r-SAK）（抗急性心肌梗死药）单次静脉给药后在健康人体内的药代动力学。方法24例健康受试者随机分为3组（5，10，15mg剂量组），建立双抗体酶联免疫吸附法（ELISA），测定r-SAK的血药浓度，用3P97药代动力学软件进行数据处理。结果r-SAK符合二房室一级消除模型，％为6．68-23．19L，AUC0-t为1．39-3．59μg·h·mL^-1,为1．35～4．37h。结论建议临床给药方法为r-SAK10mg、30min内静脉输注。
Objective To investigate the pharmacokinetics of recombinant staphylokinase （r- SAK） by intravenous administration in healthy Chinese volunteers. Methods Twenty -four volunteers were divided into three groups, each group received a dose of 5,10,15 mg r - SAK iv infusion, respectively. The plasma concentrations of r - SAK were detec- ted by dual antibody enzyme linked immunosorbent assay method. The pharmacokinetic parameters were calculated with 3P97 program. Results The pharmacokinetics of r - SAK was adapted to two - compartment first order elimination model. The pharmacokinetic parameters were as follows： Vc was 6.68-23. 19 L, AUCo-t was 1.39-3.59μg · h · mL^-1 , t1/2β was 1.35 -4.37 L, respectively. Conclusion It showed that intravenous administration of 10 mg r- SAK in 30 minutes was suggested.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2007年第2期97-100,共4页
The Chinese Journal of Clinical Pharmacology
关键词
重组葡激酶
药代动力学
酶联免疫吸附法
recombinant staphylokinase
pharmacokinetics
enzyme linked immunosorbent assay
